News | PET-CT | February 23, 2021

Model Helps Predict Which Patients will Benefit Most from PSMA PET Scan

Findings indicate that PPC and GG are highly predictive of overall upstaging by PSMA PET/CT for patients with high-risk prostate cancer

Findings indicate that PPC and GG are highly predictive of overall upstaging by PSMA PET/CT for patients with high-risk prostate cancer

Image courtesy of UCLA Health

February 23, 2021 — A new study led by researchers at the UCLA Jonsson Comprehensive Cancer Center helps identify which patients with prostate cancer will benefit most from the use of prostate-specific membrane antigen PET imaging, PSMA PET, a novel imaging technique that recently was approved by the U.S. Food and Drug Administration.

By studying different variables and risk factors, researchers created a model that can be used in the clinic to identify patients who may have more extensive disease than anticipated and identify patients who are at higher risk of prostate cancer spreading to lymph nodes in the pelvis and beyond. The team found the percent of positive cores -- a metric that reflects volume of disease -- is a powerful predictor of increased nodal, metastatic and any upstaging in men with newly diagnosed high-risk prostate cancer. Patients with PPC greater than 50% and had a Gleason score of 9 or 10 (Gleason grade group 5) are the most likely to benefit from getting the PSMA PET scan.

The PSMA PET scan is an emerging imaging modality with improved sensitivity and specificity over conventional imaging for prostate cancer staging. It uses positron emission tomography (PET) in conjunction with a tracer that is highly effective in detecting prostate cancer throughout the body so the precise location of the full extent of disease can be visualized. The PSMA PET scan identifies cancer that is often missed by current standard-of-care imaging techniques. However, this scan is still not widely available and resource allocation may be a problem. Therefore, it is imperative to identify patients who are most likely to benefit from this novel imaging technique.

The team looked at 213 men who were enrolled in two prospective clinical trials at UCLA that used the PSMA PET scan as a part of primary staging of the disease. They used a multivariable logistic regression model to assess for predictors of upstaging and developed a risk calculator to further quantify the risk for each individual patient.

The findings could help predict which patients may have more cancer than anticipated, spreading to pelvic lymph nodes and beyond. An easy-to-use nomogram (calculator) was also developed as part of the effort. This is crucial for designing optimal treatment plans for each individual patient.

For more information: www.uclahealth.org

Related Content

Estimates of excess deaths, defined as the number of persons who have died from all causes, above the expected number of deaths for a given place and time, can provide a comprehensive account of mortality likely related to the COVID-19 pandemic, including deaths that are both directly and indirectly associated with COVID-19.
News | Coronavirus (COVID-19) | May 13, 2021
May 13, 2021 — Estimates of excess deaths, defined as the number of persons who have died from all causes, above the
Medical researchers at Flinders University have established a new link between high body mass index (BMI) and breast cancer survival rates — with clinical data revealing worse outcomes for early breast cancer (EBC) patients and improved survival rates in advanced breast cancer (ABC).

Getty Images

News | Women's Health | May 13, 2021
May 13, 2021 — Medical researchers at Flinders University
News | Artificial Intelligence | May 11, 2021
May 11, 2021 — Whiterabbit, an AI technology company focused on early...